All Updates

All Updates

icon
Filter
Funding
Cartesian Therapeutics raises USD 130 million in PIPE funding to develop ongoing pipeline programs
Cell & Gene Therapy
Jul 2, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jul 2, 2024

Cartesian Therapeutics raises USD 130 million in PIPE funding to develop ongoing pipeline programs

Funding

  • Autoimmune-focused mRNA cell therapy developer Cartesian Therapeutics has secured USD 130 million in a Private Investment in Public Equity (PIPE) investment round, led by Leerink Partners and TD Cowen, with participation from HBM Healthcare Investments (Cayman) Ltd., Invus, and Schooner Capital, among others. The funding round is expected to be closed on or about July 3, 2024, subject to satisfaction of closing conditions.

  • The funds raised will be used to finance the company's ongoing pipeline programs, address general corporate requirements, and augment the company's working capital. The company also plans to conduct a Phase II basket trial in additional autoimmune indications. 

  • Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. Its proprietary RNA Armory platform facilitates the precise engineering of cells to deliver mRNA therapies directly to disease sites, enabling safe and effective treatments. Cartesian's lead product, Descartes-08, is an autologous mRNA CAR-T therapy targeting B-cell maturation antigen (BCMA) and is in Phase IIb clinical development for myasthenia gravis (MG). The company is also developing Descartes-15, a next-generation mRNA CAR T therapy​ for autoimmune indications and multiple myeloma.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.